• Skip to main content
  • Skip to primary sidebar

An Inconvenient Truth: This Is a Woman

Don’t Get Angry, Get Active!

Hide Search

Vical Pandemic Influenza Vaccine Shows Strong Results in H1N1 Study

H. Sandra Chevalier-Batik · September 11, 2009 ·

Vical vax demonstrates cross-reactivity against California,Texas and Mexico H1N1 strains

Vical Pandemic Influenza Vaccine Demonstrates Cross-reactivity Against California, Texas and Mexico H1N1 Strains

Vical Incorporated (Nasdaq:VICL) announced today that the company’s DNA vaccine against A/H1N1 pandemic influenza (swine flu) has demonstrated robust immune responses in 100% of vaccinated animals against virus strains isolated from recent outbreaks in three distinct geographic locations — California, Texas and Mexico.

Vical’s plasmid DNA vaccine contains the H1 hemagglutinin gene sequence provided by the U.S. Centers for Disease Control and Prevention (CDC) for the swine-origin A/California/04/09 pandemic influenza virus, and after two doses produced immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits using HI assays against the swine-origin A/California/07/09 x-179a, A/Texas/15/09 and A/Mexico/4108/09 influenza viruses. Hemagglutination inhibition (HI) titers were well above the protection threshold of 40, ranging from 320 to 2,560 in mice, and from 640 to 2,560 in rabbits against the California strain. Results against the Texas and Mexico strains were essentially equivalent, ranging from 640 to 2,560 in both mice and rabbits. Vical’s vaccine would also be expected to provide similar robust immune responses against other swine-origin A/H1N1 influenza virus subtypes, supporting selection of a single A/H1N1 virus strain as the basis for the vaccine.

“Cross-reactivity is consistent with previous CDC reports that circulating strains of swine-origin A/H1N1 pandemic influenza have remained antigenically homogeneous,” said Vijay B. Samant, President and Chief Executive Officer of Vical, “but future viral changes are unpredictable and could be far more substantial. The inherent speed of our DNA vaccine platform both in initial development and manufacturing could be extremely important in addressing the potential shortfalls of conventional vaccine approaches.”

Vical has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC), a biomedical research organization within the U.S. Navy, to develop a vaccine against H1N1 influenza.

“We are working with the U.S. Navy to secure funding to advance our H1 vaccine into human clinical testing,” added Mr. Samant. “Based on the sustained threat from the ongoing H1N1 pandemic, we have initiated critical-path manufacturing activities to allow initiation of a Phase 1 trial in as little as four to six weeks after funding is secured.”

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Vical’s vaccine technologies and their potential application in a vaccine against H1N1 influenza, potential human clinical testing of such a vaccine, the Vical/NMRC CRADA, potential changes in circulating strains of influenza, potential government regulatory and procurement activities, as well as the company’s focus, collaborative partners, and product candidates. Risks and uncertainties include whether the company’s technologies will be successfully applied for the development of an H1 DNA vaccine; whether such vaccine will advance to clinical testing quickly, if at all; whether funding will be secured to support a Phase 1 trial; whether Vical, NMRC or others will continue development of any influenza DNA vaccine candidates; whether Vical and/or NMRC will terminate the CRADA before achievement of its objectives; whether the company’s DNA vaccine candidate will be effective in protecting humans against H1N1 or any other strains of influenza; whether H1N1 pandemic influenza will undergo substantial strain changes; whether Vical’s pandemic influenza vaccine will advance sufficiently to be considered for licensure during future pandemics; whether results in animal testing will be predictive of results in human testing; whether any product candidates will be shown to be safe and effective; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT: Vical Incorporated
         Alan R. Engbring
         (858) 646-1127
         www.vical.com
Source Vical Press Release
Share

Filed Under: Influenza A Virus H1N1 Strain Tagged With: H1N1 andemic influenza preparedness efforts, swine flu vaccine, Swine flu vaccine production, Vical

Primary Sidebar

Categories

  • Attention-Deficit/Hyperactivity Disorder Medications
  • Big Pharma Watch
  • Biotech Industry
  • Birth Control
  • Breast Cancer
  • cáncer de cuello uterino
  • Cancer Research
  • Cervarix
  • Cervical Cancer
  • Clinical Trials
  • Diabetes
  • Domestic Violence
  • Drug Approvals
  • Emotional Health
  • FDA
  • FDA Black Box Warning
  • FDA Clinical Trials
  • FDA Failure To Protect
  • FDA Product Recall
  • Follow The Money
  • Gardasil
  • Gardasil®
  • Gender Bias
  • Gender Politics
  • genital warts
  • Guillain-Barre Syndrome
  • Hormone Cycle
  • HPV Infection
  • HPV Vaccine
  • HRT
  • HRT Side Effects
  • Influenza A Virus H1N1 Strain
  • Mammograms
  • Mandatory HPV Vaccination Policies
  • Medical Technology
  • Menopause
  • MERCK Watch
  • MMR vaccine
  • National Vaccine Injury Compensation Program
  • PAP Test
  • Prescription Drug Side Effects
  • Proactive Nutrition
  • Product Recall
  • Reproductive Health
  • Sexual Dysfunction
  • Sleep Loss
  • STD Infection
  • Stroke
  • Take Action!
  • Uncategorized
  • Unwanted Pregnancy
  • Vaccination Policy
  • VAERS
  • vaginal yeast infection
  • Virginity
  • Weight Gain
  • Women's Health
  • Women's Rights
  • Work Place Issues
  • World Health Organization
  • Yeast Infection
  • Your Body/Your Self

Archives

  • February 2010
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • March 2006
  • September 2005
  • June 2005
  • May 2005
  • December 2004
April 2025
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  
« Feb    

Breast Cancer

  • Cancer Advocacy

Health Advocacy

  • Women’s Universal Health Initiative

Syndication

  • FDA MedWatch

Tags

Big Pharma Watch Birth Control Breast Cancer Cancer Cancer Research CDC Cervarix Cervical Cancer Children's Health Exploitive Behavior FDA FDA Approvals FDA Clinical Trials FDA Failure To Protect FDA Press Release Follow The Money Gardasil Gardasil Adverse Event Gardasil® GlaxoSmithKline GlaxoSmithKline Cervarix Gynecology H1N1 "swine flu" virus H1N1 pandemic influenza preparedness efforts Health Advisory HPV HPV-Associated Cervical Cancer HPV-Vaccination HPV Infection HPV Vaccine HRT Human Papillomavirus (HPV) Infection Merck PAP SMEAR PAP Test Proactive Nutrition Questionable Medicine STD Infection STD Vaccination swine flu vaccine Swine flu vaccine production Take Action! Uncategorized Woman’s Health Your Body/Your Self

Copyright © 2010-2025 Hands On WordPress · All Rights Reserved